Publique en esta revista
Información de la revista
Vol. 6. Núm. A.
Actualización y futuro del óxido nítrico en el tratamiento de la enfermedad cardiovascular
Páginas 41A-50A (Marzo 2006)
Compartir
Compartir
Descargar PDF
Más opciones de artículo
Vol. 6. Núm. A.
Actualización y futuro del óxido nítrico en el tratamiento de la enfermedad cardiovascular
Páginas 41A-50A (Marzo 2006)
Actualización y futuro del óxido nítrico en el tratamiento de la enfermedad cardiovascular
DOI: 10.1016/S1131-3587(06)74819-1
Acceso a texto completo
Papel de los nitratos en el tratamiento de la enfermedad cardiovascular
Role of Nitrates in the Treatment of Cardiovascular Diseases
Visitas
...
Esteban López de Sáa,??
Autor para correspondencia
e.lopezdesa@terra.es

Correspondencia: Dr. E. López de Sá. Unidad Coronaria Hospital Gerenal Universitario Gregorio Marañón. Dr. Esquerdo, 46. 28007 Madrid. España.
, Álvaro Estéveza, José Onaindíab, Rafael Rubioa, José López-Sendónc
a Unidad Coronaria. Hospital General Universitario Gregorio Marañón. Madrid. España
b Servicio de Cardiología. Hospital de Galdakao. Vizkaya. España
c Servicio de Cardiología. Hospital Universitario La Paz. Madrid. España
Información del artículo
Resumen
Bibliografía
Descargar PDF
Estadísticas

Los nitratos orgánicos, en sus diferentes presentaciones, han constituido uno de los pilares para el tratamiento de las enfermedades cardiovasculares durante más de 100 años. Los nitratos son donadores de óxido nítrico; por tanto, su efecto primordial es el de la relajación del músculo liso endotelial. Producen dilatación venosa y arterial, por lo que reducen la precarga y la poscarga. Sus principales indicaciones son el tratamiento sintomático de la angina de esfuerzo estable, el síndrome coronario agudo, y la insuficiencia cardíaca aguda y crónica. Asimismo, añadidos a la terapia convencional en pacientes afroamericanos con insuficiencia cardíaca crónica, en asociación con la hidralazina, producen una reducción de la mortalidad. Su papel actual en pacientes de otras razas aún se desconoce.

La principal limitación de esta terapia es el desarrollo de tolerancia, que conduce a la atenuación de los efectos farmacológicos antiisquémicos, antianginosos y hemodinámicos con la utilización continuada. En la práctica clínica, lo más conveniente para reducir al mínimo la tolerancia es utilizar la menor dosis necesaria y dejar un intervalo libre de nitratos, para permitir la recuperación del endotelio.

Palabras clave:
Nitratos
Angina estable
Síndrome coronario agudo
Insuficiencia cardíaca

For more than 100 years, organic nitrates, in one form or another, have formed one the central pillars of the treatment of cardiovascular disease. As nitrates are nitric oxide donors, their main effect is to induce endothelial smooth muscle relaxation. Nitrates induce both venous and arterial dilatation, thereby reducing both preload and afterload. They are principally indicated for the symptomatic treatment of stable angina, acute coronary syndromes, and acute and chronic heart failure. Moreover, nitrates also reduce mortality in Afro-americans when given with hydralazine as an addition to conventional therapy. Their role in other ethnic groups is unknown. The main limitation of nitrate therapy is that its continued use leads to the development of tolerance, with reductions in anti-ischemic and hemodynamic effects. Clinically, the most appropriate way of minimizing tolerance is to use the lowest acceptable dose and to introduce nitrate-free periods to enable recovery of the endothelium.

Key words:
Nitrates
Stable angina
Acute coronary syndrome
Heart failure
El Texto completo está disponible en PDF
Bibliografía
[1.]
Nitroglycerin. Encyclopædia Britannica. 2005, de Encyclopædia Britannica Premium Service [accedido 29 Ag 2005). Disponible en: http://www.britannica.com/eb/article-9055952.
[2.]
W.B. Fye.
T. Lauder Brunton and amyl nitrite: a Victorian vasodilator.
Circulation, 74 (1986), pp. 222-229
[3.]
W. Murrel.
Nitroglycerin as a remedy for angina pectoris.
Lancet, I (1879), pp. 80-81
[4.]
J. Abrams.
Mechanisms of action of the organic nitrates in the treatment of myocardial ischemia.
Am J Cardiol, 70 (1992), pp. B30-B42
[5.]
J.L. Dinerman, D.L. Lawson, J.L. Mehta.
Interactions between nitroglycerin and endothelium in vascular smooth muscle relaxation.
Am J Physiol, 260 (1991), pp. H698-H701
[6.]
E. Bassenge, J. Zanzinger.
Nitrates in different vascular beds, nitrate tolerance, and interactions with endothelial function.
Am J Cardiol, 70 (1992), pp. B23-B29
[7.]
J. Abrams.
How to use nitrates.
Cardiovasc Drugs Ther, 16 (2002), pp. 511-514
[8.]
B.I. Jugdutt.
Nitrates in instable angina and acute myocardial infarction.
Nitrate therapy and nitrate tolerante, pp. 111-167
[9.]
Y.Y. Chirkov, L.P. Chirkova, J.D. Horowitz.
Nitroglycerin tolerance at the platelet level in patients with angina pectoris.
Am J Cardiol, 80 (1997), pp. 128-131
[10.]
B.I. Jugdutt, J.W. Warnica.
Tolerance with low dose intravenous nitroglycerin therapy in acute myocardial infarction.
Am J Cardiol, 64 (1989), pp. 581-587
[11.]
D. Zimrin, N. Reichek, K.T. Bogin, G. Aurigemma, P. Douglas, B. Berko, et al.
Antianginal effects of intravenous nitroglycerin over 24 hours.
Circulation, 77 (1988), pp. 1376-1384
[12.]
U. Elkayam, A. Mehra, A. Shotan, E. Ostrzega.
Nitrate resistance and tolerance: potential limitations in the treatment of congestive heart failure.
Am J Cardiol, 70 (1992), pp. B98-B104
[13.]
B. Fink, M. Schwemmer, N. Fink, E. Bassenge.
Tolerance to nitrates with enhanced radical formation suppressed by carvedilol.
J Cardiovasc Pharmacol, 34 (1999), pp. 800-805
[14.]
G. Berkenboom, D. Fontaine, P. Unger, S. Baldassarre, N. Preumont.
Absence of nitrate tolerance after long-term treatment with ramipril: an endothelium-dependent mechanism.
J Cardiocasc Pharmacol, 34 (1999), pp. 547-553
[15.]
V. Elkayam, J.V. Johnson, A. Shutan, S. Bokhari, A. Soldky, M. Canetti, et al.
Double-blind, placebo-controlled study to evaluate the effects of organic nitrates in patients with heart failure treated with IECA.
Circulation, 99 (1999), pp. 2652-2657
[16.]
M. Sarr, I. Lobysheva, A.S. Diallo, J.C. Stoclet, V.B. Schini-Kerth, B. Muller.
Formation of releasable NO stores by S-nitrosoglutathione in arteries exhibiting tolerance to glyceryl-trinitrate.
Eur J Pharmacol, 513 (2005), pp. 119-123
[17.]
M.M. Bassan, D. Weiler-Ravell, O. Shalev.
Comparison of the antianginal effectiveness of nifedipine, verapamil, and isosorbide dinitrate in patients receiving propranolol: a double-blind study.
Circulation, 68 (1983), pp. 568-575
[18.]
F. Akhras, G. Jackson.
Efficacy of nifedipine and isosorbide mononitrate in combination with atenolol in stable angina.
Lancet, 338 (1991), pp. 1036-1039
[19.]
P.A. Heidenreich, K.M. McDonald, T. Hastie, B. Fadel, V. Hagan, B.K. Lee, et al.
Meta-analysis of trials comparing beta-blockers, calcium antagonists, and nitrates for stable angina.
JAMA, 281 (1999), pp. 1927-1936
[20.]
R.J. Wainwright, J.P. Foran, S.F. Padaria, F. Akhras, G. Jackson, A.R. Clark.
The long-term safety and tolerability of transdermal glyceryl trinitrate, when used with a patch-free interval in patients with stable angina.
Br J Clin Pract, 47 (1993), pp. 178-182
[21.]
R.J. Gibbons, J. Abrams, K. Chatterjee, J. Daley, P.C. Deedwania, J.S. Douglas, et al.
ACC/AHA 2002 guideline update for the management of patients with chronic stable angina-summary article: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines (Committee on the Management of Patients With Chronic Stable Angina).
J Am Coll Cardiol, 41 (2003), pp. 159-168
[22.]
J.A. Cairns.
Medical management of unstable angina.
Lancet, 346 (1995), pp. 1644-1645
[23.]
X. Bosch, E. López de Sá, J. López Sendón, J. Aboal, F. Miranda-Guardiola, A. Bethencourt, et al.
Perfil clínico, pronóstico y variabilidad en el tratamiento del síndrome coronario agudo sin elevación del segmento ST. Datos del registro PEPA.
Rev Esp Cardiol, 56 (2003), pp. 346-353
[24.]
K.D.R. Kaplan, M. Parker, J. Przybylek, J.R. Teagarden, M. Lesch.
Intravenous nitroglycerin for the treatment of angina at rest unresponsive to standard nitrate therapy.
Am J Cardiol, 51 (1983), pp. 694-698
[25.]
N. DePace, I.M. Herling, M.N. Kotler, A.H. Hakki, S.R. Spielman, B.L. Segal.
Intravenous nitroglycerin for rest angina. Potential pathophysiologic mechanisms of action.
Arch Intern Med, 142 (1982), pp. 1806-1809
[26.]
J.R. Mikolich, N.B. Nicoloff, P.H. Robinson, R.B. Logue.
Relief of refractory angina with continuous intravenous infusion of nitroglycerin.
Chest, 77 (1980), pp. 375-379
[27.]
G. Curfman, J.A. Heinsimr, E.C. Lozner, H.L. Fung.
Intravenous nitroglycerin in the treatment of spontaneous angina pectoris: a prospective randomized trial.
Circulation, 67 (1983), pp. 276-282
[28.]
M. Dellborg, G. Gustafsson, K. Swedberg.
Buccal versus intravenous nitroglycerin in unstable angina pectoris.
Eur J Clin Pharmacol, 41 (1991), pp. 5-9
[29.]
J. Figueras, R. Lidon, J. Cortadellas.
Rebound myocardial ischaemia following abrupt interruption of intravenous nitroglycerin infusion in patients with unstable angina at rest.
Eur Heart J, 12 (1991), pp. 405-411
[30.]
E. Braunwald, E.M. Antman, J.W. Beasley, R.M. Califf, M.D. Cheitlin, J.S. Hochman, et al.
ACC/AHA guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction-2002: summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Unstable Angina).
Circulation, 106 (2002), pp. 1893-1900
[31.]
M.E. Bertrand, M.L. Simoons, K.A. Fox, L.C. Wallentin, C.W. Hamm, E. McFadden, et al.
Management of acute coronary syndromes in patients presenting without persistent ST-segment elevation.
Eur Heart J, 23 (2002), pp. 1809-1840
[32.]
A.D. Levison, J.L. Velianou, S. Yusuf.
Nitrates.
Clinical trials in cardiovascular disease: a companion to Braunwald's heart disease, pp. 131-144
[33.]
W.D. Bussmann, D. Passek, W. Seidel, M. Kaltenbach.
Reduction of CK and CK-MB indexes of infarct size by intravenous nitroglycerin.
Circulation, 63 (1981), pp. 615-622
[34.]
Y.I. Kim, J.F. Williams Jr.
Large dose sublingual nitroglycerin in acute myocardial infarction: relief of chest pain and reduction of Q wave evolution.
Am J Cardiol, 49 (1982), pp. 842-848
[35.]
B.I. Jugdutt.
Nitrates in myocardial infarction.
Cardiovasc Drugs Ther, 8 (1994), pp. 635-646
[36.]
S. Yusuf, R. Collins, S. MacMahon, R. Peto.
Effect of intravenous nitrates on mortality in acute myocardial infarction: an overview of the randomised trials.
Lancet, 1 (1988), pp. 1088-1092
[37.]
ISIS-4 investigators.
ISIS-4: a randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction. ISIS-4 (Fourth International Study of Infarct Survival) Collaborative Group.
Lancet, 345 (1995), pp. 669-685
[38.]
H.S. Mellen, H.S. Goldberg, H.F. Friedman.
Therapeutic effects of pentaerythritol tetranitrate in the immediate postmyocardial-infarction period.
N Engl J Med, 276 (1967), pp. 319-322
[39.]
D.J. Newell.
Pentaerythritol tetranitrate (sustained action) in acute myocardial infarction.
Br Heart J, 32 (1970), pp. 16-20
[40.]
A. Oscharoff.
Pentaerythritol tetranitrate, as adjunct therapy in the immediate postinfarction period.
Angiology, 15 (1964), pp. 505-514
[41.]
T.J. Ryan, M. Schnee.
Pentaerythritol tetranitrate in acute myocardial infarction (abstract).
Circulation, 32 (1965), pp. II105
[42.]
GISSI-3 investigators.
GISSI-3: effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Gruppo Italiano per lo Studio della Sopravvivenza nell’infarto Miocardico.
Lancet, 343 (1994), pp. 1115-1122
[43.]
ESPRIM investigators.
The ESPRIM trial: short-term treatment of acute myocardial infarction with molsidomine. European Study of Prevention of Infarct with Molsidomine (ESPRIM) Group.
Lancet, 344 (1994), pp. 91-97
[44.]
F. Van de Werf, D. Ardissino, A. Betriu, D.V. Cokkinos, E. Falk, K.A. Fox, et al.
Management of acute myocardial infarction in patients presenting with ST-segment elevation. The Task Force on the Management of Acute Myocardial Infarction of the European Society of Cardiology.
Eur Heart J, 24 (2003), pp. 28-66
[45.]
E.M. Antman, D.T. Anbe, P.W. Armstrong, E.R. Bates, L.A. Green, M. Hand, et al.
ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction-executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1999 Guidelines for the Management of Patients With Acute Myocardial Infarction).
Circulation, 110 (2004), pp. 588-636
[46.]
G. Cotter, E. Metzkor, E. Kaluski, Z. Faigenberg, R. Miller, A. Simovitz, et al.
Randomised trial of high-dose isosorbide dinitrate plus low-dose furosemide versus high-dose furosemide plus lowdose isosorbide dinitrate in severe pulmonary oedema.
[47.]
M.S. Nieminen, M. Bohm, M.R. Cowie, H. Drexler, G.S. Filippatos, G. Jondeau.
Executive summary of the guidelines on the diagnosis and treatment of acute heart failure: the Task Force on Acute Heart Failure of the European Society of Cardiology.
Eur Heart J, 26 (2005), pp. 384-416
[48.]
U. Elkayam, J.V. Johnson, A. Shotan, S. Bokhari, A. Solodky, M. Canetti, et al.
Double-blind, placebo-controlled study to evaluate the effect of organic nitrates in patients with chronic heart failure treated with angiotensin-converting enzyme inhibition.
Circulation, 99 (1999), pp. 2652-2657
[49.]
B.I. Jugdutt, M.I. Khan.
Effect of prolonged nitrate therapy on left ventricular remodeling after canine acute myocardial infarction.
Circulation, 89 (1994), pp. 2297-2307
[50.]
M. Anguita Sánchez.
Investigadores del Registro BADAPIC. Características clínicas, tratamiento y morbimortalidad a corto plazo de pacientes con insuficiencia cardíaca controlados en consultas específicas de insuficiencia cardíaca. Resultados del Registro BADAPIC.
Rev Esp Cardiol, 57 (2004), pp. 1159-1169
[51.]
M. Komajda, F. Follath, K. Swedberg, J. Cleland, J.C. Aguilar, A. Cohen-Solal, et al.
The EuroHeart Failure Survey programme-a survey on the quality of care among patients with heart failure in Europe. Part 2: treatment.
Eur Heart J, 24 (2003), pp. 464-474
[52.]
J.N. Cohn, D.G. Archibald, S. Ziesche, J.A. Franciosa, W.E. Harston, F.E. Tristani, et al.
Effect of vasodilator therapy on mortality in chronic congestive heart failure. Results of a Veterans Administration Cooperative Study.
N Engl J Med, 314 (1986), pp. 1547-1552
[53.]
J.N. Cohn, G. Johnson, S. Ziesche, F. Cobb, G. Francis, F. Tristani, et al.
A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure.
N Engl J Med, 325 (1991), pp. 303-310
[54.]
A.L. Taylor, S. Ziesche, C. Yancy, P. Carson, R D’Agostino Jr, K. Ferdinand, et al.
Combination of isosorbide dinitrate and hydralazine in blacks with heart failure.
N Engl J Med, 351 (2004), pp. 2049-2057
[55.]
J.N. Cohn, D.G. Archibald, G.S. Francis, S. Ziesche, J.A. Franciosa, W.E. Harston, et al.
Veterans Administration Cooperative Study on Vasodilator Therapy of Heart Failure: influence of prerandomization variables on the reduction of mortality by treatment with hydralazine and isosorbide dinitrate.
Circulation, 75 (1987), pp. IV49-54
[56.]
C.W. Yancy.
Heart failure in African Americans: a cardiovascular engima.
J Card Fail, 6 (2000), pp. 183-186
[57.]
L. Kalinowski, I. Dobrucki, T. Malinski.
Race-specific differences in endothelial function: predisposition of African Americans to vascular disease.
Circulation, 109 (2004), pp. 2511-2517
[58.]
D.J. Dries, C.W. Yancy, M.A. Strong, M.H. Drazner.
Racial response to angiotensin-converting enzyme therapy in systolic heart failure.
Congest Heart Fail, 10 (2004), pp. 30-33
[59.]
K. Swedberg, J. Cleland, H. Dargie, H. Drexler, F. Follath, M. Komajda, et al.
Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology.
Eur Heart J, 26 (2005), pp. 1115-1140
[60.]
M.D. Cheitlin, A.M. Hutter Jr, R.G. Brindis, P. Ganz, S. Kaul, R.O. Russell Jr, et al.
ACC/AHA expert consensus document. Use of sildenafil (Viagra) in patients with cardiovascular disease. American College of Cardiology/American Heart Association.
J Am Coll Cardiol, 33 (1999), pp. 273-282
Copyright © 2006. Sociedad Española de Cardiología
Idiomas
Revista Española de Cardiología

Suscríbase a la newsletter

Opciones de artículo
Herramientas
es en

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?